Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

ABSTRACT:

Unlabelled

In postmenopausal women with low bone mass and hormone-receptor-positive breast cancer on an aromatase inhibitor, risedronate maintained skeletal health assessed by bone density and turnover markers. Women with the greatest decreases in bone turnover markers at 12 months had the greatest increases in bone density at 24 months.

Introduction

Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone-receptor-positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if (1) oral bisphosphonate therapy can prevent bone loss in women on an AI and (2) early changes in bone turnover markers (BTM) can predict later changes in bone mineral density (BMD).

Methods

We conducted a 2-year double

SUBMITTER: Greenspan SL 

PROVIDER: S-EPMC4766869 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature